Discover
Lynparza (olaparib) / Merck (MSD), AstraZeneca; Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaOverview of the Updated NCCN Guidelines on Ovarian Cancer (Journal of Clinical Pathways) - Jun 17, 2020 - "The Guidelines added niraparib to maintenance therapy options for those with complete or partial remission if they have BRCA1/2 wild-type or unknown and did not use bevacizumab as primary therapy or for those with germline or somatic BRCA1/2 mutation (category 1 if bevacizumab was not used as a primary therapy, and category 2A if it was). The Guidelines modified a category of evidence for olaparib for patients with a germline or somatic BRCA1/2 mutation who did not receive bevacizumab during primary therapy..."
Rubraca (rucaparib) / ClovisRubraca: Newly added patents in Orange Book (Orange Book) - Jun 17, 2020 - Expiry on July 23, 2024, August 12, 2027, August 4, 2031 and August 17, 2035
Zejula (niraparib) / GSK, ZAI Lab, J&J, Takeda; dostarlimab (TSR-042) / GSKA Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (clinicaltrials.gov) - Jun 18, 2020 - P3; N=1228; Recruiting; Sponsor: Tesaro, Inc.; Trial completion date: Jan 2023 --> Jul 2026; Trial primary completion date: Jul 2021 --> Feb 2023
